Synlogic, Inc. SYBX

SYBX Company Overview

Synlogic, Inc. (NASDAQ: SYBX) is a biotechnology company focused on developing engineered microbial therapeutics, often referred to as “synthetic biotics,” for the treatment of metabolic and immune-mediated diseases. The company operates within the broader biotechnology and synthetic biology industries, with research centered on programming naturally occurring bacteria to perform therapeutic functions inside the human body. Its primary historical revenue and value drivers have been research and development programs tied to rare metabolic disorders and inflammatory diseases rather than commercialized product sales.

The company’s pipeline historically included candidates targeting phenylketonuria (PKU), homocystinuria, enteric hyperoxaluria, and inflammatory bowel disease. Synlogic differentiated itself through its proprietary synthetic biology platform designed to engineer probiotic bacteria capable of metabolizing toxic compounds or delivering therapeutic activity directly in the gastrointestinal tract. Founded in 2014 through the merger of Synlogic Operating Company and Mirna Therapeutics’ synthetic biology assets, the company evolved from an early-stage synthetic biology platform developer into a clinical-stage therapeutics company pursuing precision microbiome-based medicines.